Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE: 002020)

Market Cap	9.61B
Revenue (ttm)	4.21B
Net Income (ttm)	705.10M
Shares Out	861.03M
EPS (ttm)	0.82
PE Ratio	13.62
Forward PE	14.06
Dividend	0.30 (2.69%)
Ex-Dividend Date	May 24, 2024

Volume	6,550,100
Open	11.44
Previous Close	11.16
Day's Range	11.04 - 11.44
52-Week Range	8.28 - 15.25
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Zhejiang Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, Cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,909
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002020

Financial Performance

In 2023, Zhejiang Jingxin Pharmaceutical's revenue was 4.00 billion, an increase of 5.79% compared to the previous year's 3.78 billion. Earnings were 618.90 million, a decrease of -6.55%.